Jaxteran

Dimethyl Fumarate, the active ingredient in Jaxteran, is an immunomodulating agent presented as an oral formulation for oral use. It is indicated for the treatment of multiple sclerosis and psoriasis in adult patients.

GNH USA supplies Jaxteran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jaxteran acts on immune pathways that are central to inflammatory demyelinating and skin disorders. - Multiple sclerosis: reduces relapse frequency and slows disability progression in adults. - Psoriasis: improves skin lesions and decreases disease activity in moderate to severe cases.

Jaxteran may cause a range of adverse reactions, from frequent mild events to rare serious conditions.

Common Side Effects: - Flushing: transient warmth and redness, often occurring after the first doses. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea. - Lymphopenia: reduction in white‑blood‑cell count, monitored by blood tests. - Headache: mild to moderate intensity, usually self‑limiting.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): a rare but severe brain infection. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Anaphylactic reactions: acute, potentially life‑threatening allergic response.

Before initiating therapy, clinicians should consider several safety measures. - Monitor lymphocyte counts: perform regular blood tests to detect lymphopenia. - Assess liver function: check baseline enzymes and repeat as clinically indicated. - Avoid in active infection: postpone treatment until infection resolves. - Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks. - Concomitant immunosuppressants: evaluate risk of additive immunosuppression. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Dimethyl fumarate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection. - Other immunosuppressive agents (e.g., azathioprine, methotrexate): increase risk of severe immunosuppression. - Strong CYP450 inducers (e.g., carbamazepine, phenytoin): may reduce drug exposure.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4: monitor for altered lipid levels. - Anticoagulants (e.g., warfarin): watch INR and adjust dose if needed. - Non‑live vaccines: assess immune response and timing of administration.